Weekly Analysts’ Ratings Updates for Charles River Laboratories International (CRL)

Several analysts have recently updated their ratings and price targets for Charles River Laboratories International (NYSE: CRL):

  • 2/23/2023 – Charles River Laboratories International had its price target lowered by analysts at Credit Suisse Group AG from $280.00 to $260.00. They now have an “outperform” rating on the stock.
  • 2/23/2023 – Charles River Laboratories International had its price target lowered by analysts at Morgan Stanley from $241.00 to $230.00. They now have an “equal weight” rating on the stock.
  • 2/23/2023 – Charles River Laboratories International had its price target lowered by analysts at Citigroup Inc. from $280.00 to $260.00. They now have a “buy” rating on the stock.
  • 2/23/2023 – Charles River Laboratories International was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $255.00 price target on the stock.

Charles River Laboratories International Trading Down 0.3 %

Shares of CRL stock opened at $202.02 on Tuesday. Charles River Laboratories International, Inc. has a 1-year low of $181.36 and a 1-year high of $308.15. The company has a current ratio of 1.32, a quick ratio of 1.08 and a debt-to-equity ratio of 0.91. The stock has a market cap of $10.30 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.41 and a beta of 1.36. The stock has a 50-day moving average of $236.02 and a 200-day moving average of $221.38.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.75 by $0.23. The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.04 billion. Charles River Laboratories International had a net margin of 12.23% and a return on equity of 20.98%. The company’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.49 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.26 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $250.00, for a total value of $5,000,000.00. Following the completion of the transaction, the chief executive officer now directly owns 216,594 shares of the company’s stock, valued at approximately $54,148,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Shannon M. Parisotto sold 4,558 shares of the stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $254.41, for a total transaction of $1,159,600.78. Following the transaction, the executive vice president now directly owns 6,010 shares of the company’s stock, valued at $1,529,004.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster sold 20,000 shares of Charles River Laboratories International stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $250.00, for a total transaction of $5,000,000.00. Following the completion of the sale, the chief executive officer now directly owns 216,594 shares of the company’s stock, valued at $54,148,500. The disclosure for this sale can be found here. Insiders sold 27,763 shares of company stock valued at $6,974,921 over the last quarter. Insiders own 1.10% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in the company. Moneta Group Investment Advisors LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $298,877,000. Price T Rowe Associates Inc. MD grew its position in Charles River Laboratories International by 399.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,104,292 shares of the medical research company’s stock valued at $236,285,000 after purchasing an additional 883,029 shares during the period. Norges Bank bought a new stake in Charles River Laboratories International during the 4th quarter valued at $97,675,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Charles River Laboratories International by 51.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 976,347 shares of the medical research company’s stock valued at $192,144,000 after buying an additional 331,084 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Charles River Laboratories International by 57.4% during the fourth quarter. Marshall Wace LLP now owns 874,773 shares of the medical research company’s stock valued at $190,613,000 after buying an additional 319,095 shares during the last quarter. 97.80% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

Recommended Stories

Receive News & Ratings for Charles River Laboratories International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc and related companies with MarketBeat.com's FREE daily email newsletter.